EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Brii Biosciences Limited (BRIBF) fair value: what the stock is really worth

We calculate from audited financials what Brii Biosciences Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN KYG1645A1094

BB Brii Biosciences Limited logo Thin data Sep 13, 2026

Brii Biosciences Limited

BRIBF · US

SpeculativeUpside exists, but weak quality makes the signal speculative.

✓Fair value $0.1609 · Undervalued (+24%)
!Quality 47/100
!Weak Growth (revenue 5y −26.1 %/yr)
!Low debt · negative free cash flow
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$2.75 $0.0028 Fair Value $0.1609 Jan 2022 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

56‑month range $0.0028 – $2.75 · fair‑value band $0.1061 – $0.2010 · the $0.1300 price screens below the $0.1609 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States.

Show more

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in c for the treatment of HIV. It also develops Soralimixinfor the treatment of multi-drug resistant or extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with treatment-refractory mycobacterium avium complex (MAC) lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.

Stock analysis

Brii Biosciences Limited (BRIBF) currently trades at $0.1300, while our model-based Fair Value estimate is $0.1609, implying the stock looks roughly 19.2% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.

Scenario range: $0.1061 (bear) to $0.2010 (bull), the price of $0.1300 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Brii Biosciences Limited reported revenue of 18.1M CNY in FY2025 versus 92.5M CNY in FY2021, a compound −33.5%/yr. Reported net income was −217M CNY in FY2025.

Key figures

Market cap $108M · P/S ratio 3.03 · EPS (TTM) $−0.0500 · Return on equity −9.1% · Return on assets (EBIT) −15.3% · Operating margin −326% · Revenue (TTM) $35.5M · Revenue growth (YoY) +24.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 50% below its 52-week high, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at 24%, BRIBF screens cheaper than that median.

Fair Value models

Bear $0.1061 Fair Value $0.1609 Bull $0.2010
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $1.65 $2.21 $3.30 54
All 1 models by family
Asset-Based
NCAV (Graham) $1.65 $2.21 $3.30 54

Open the full fair value analysis →

Notify me when BRIBF reaches fair value

Put BRIBF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 47/100

Of which business quality 47 · Market factors (momentum, volatility) 11

Profitability 1
Margins and returns on capital today
Quality Growth 49
Are margins and returns improving?
Cashflow 18
Earnings quality: real cash, not paper profit
Fin. Strength 72
Balance sheet, leverage, solvency risk
Investment 85
Disciplined investing over empire-building
Low Volatility 22
Calm price path (market factor)
Momentum 10
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 88
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−63.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−29.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−26.1%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,091.0% (2020) → −1,632.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch BRIBF, get fair value alerts →

Compare Brii Biosciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $515.44 $566.98 +10%
Regeneron Pharmaceuticals, Inc REGN $781.49 $1,241 +59%
argenx SE ARGX €853.80 €752.12 −12%
BeOne Medicines AG 688235 ¥247.30 ¥124.62 −50%
Samsung Biologics Co 207940 1,415,000 KRW 1,556,500 KRW +10%
Alnylam Pharmaceuticals, Inc ALNY $248.68 $211.88 −15%
Royalty Pharma plc RPRX $58.61 $24.22 −59%
Celltrion, Inc 068270 178,200 KRW 74,519 KRW −58%
BioNTech SE BNTX $96.73 $63.31 −35%
Incyte Corporation INCY $121.47 $204.93 +69%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Brii Biosciences Limited · Fair Value
$0.1609 +19%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Brii Biosciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/BRIBF

Frequently asked questions

Is Brii Biosciences Limited (BRIBF) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $0.1609 versus a price of $0.1300, about +24% upside (undervalued).
What is the fair value of BRIBF?
Our model-based fair value for Brii Biosciences Limited is $0.1609 (as of Sep 13, 2026), built from audited fundamentals. The current price: $0.1300.
What is the quality score of BRIBF?
Brii Biosciences Limited has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Brii Biosciences Limited (BRIBF)?
Our model-based price target is the fair value of $0.1609 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario $0.1061, optimistic scenario $0.2010. It is a calculation from audited fundamentals, not an analyst target.
What is the Brii Biosciences Limited stock forecast for 2026?
Our models put fair value at $0.1609, about +24% upside versus a price of $0.1300 (undervalued). Cautious scenario $0.1061, optimistic scenario $0.2010. The calculation is refreshed regularly with new filings.
What is the revenue of Brii Biosciences Limited (BRIBF)?
Brii Biosciences Limited reported trailing-twelve-month revenue of about $35.5M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Brii Biosciences Limited (BRIBF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Brii Biosciences Limited it is $0.1609 per share (as of Sep 13, 2026), against a price of $0.1300. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Brii Biosciences Limited stock overvalued or undervalued in 2026?
As of Sep 13, 2026, BRIBF trades below its calculated fair value: price $0.1300, fair value $0.1609, a gap of about +24% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BRIBF?
No. The price is what the market pays today ($0.1300); the fair value is what the company's own numbers justify ($0.1609). For Brii Biosciences Limited the two are $0.0309 per share apart. That gap is exactly why we show both numbers side by side.
How much is Brii Biosciences Limited worth?
The market values Brii Biosciences Limited at about $108M (market capitalisation, as of Sep 13, 2026). Per share that is $0.1300; our models calculate a fair value of $0.1609 per share.
What do the bullish and bearish scenarios say about BRIBF?
Our models span a range for Brii Biosciences Limited: cautious scenario $0.1061, base $0.1609, optimistic $0.2010 per share (as of Sep 13, 2026, price $0.1300). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is BRIBF from its 52-week high?
Brii Biosciences Limited trades at $0.1300, about 50% below its 52-week high of $0.2600 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1609 is for.
Which stocks are comparable to Brii Biosciences Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Brii Biosciences Limited stock attractive at the current price?
The data as of Sep 13, 2026: price $0.1300, calculated fair value $0.1609 (+24%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BRIBF calculated?
We run Brii Biosciences Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1609, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Brii Biosciences Limited currently trades 24 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Brii Biosciences Limited right now?
Solid quality (47/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($0.1061 to $0.2010) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Brii Biosciences Limited

How large is the market capitalisation of Brii Biosciences Limited (BRIBF)?
The market capitalisation of Brii Biosciences Limited is $108M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Brii Biosciences Limited (BRIBF)?
The price-to-sales ratio of Brii Biosciences Limited is 3.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Brii Biosciences Limited (BRIBF)?
Earnings per share at Brii Biosciences Limited are $−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Brii Biosciences Limited (BRIBF)?
The return on equity (ROE) of Brii Biosciences Limited is −9.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Brii Biosciences Limited (BRIBF)?
On an EBIT basis the return on assets of Brii Biosciences Limited is −15.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Brii Biosciences Limited (BRIBF)?
The operating margin of Brii Biosciences Limited is −326% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Brii Biosciences Limited (BRIBF)?
Revenue at Brii Biosciences Limited is growing +24.4% versus a year earlier (3y avg −29.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Brii Biosciences Limited (BRIBF) generate?
The free cash flow of Brii Biosciences Limited is −$288M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Brii Biosciences Limited (BRIBF) hold?
Brii Biosciences Limited holds more cash than debt, $600M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Continue in the live analysis

Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.

Open the live analysis →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.